Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Inventory (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Inventory data on record, last reported at $459000.0 in Q3 2025.

  • For Q3 2025, Inventory fell 69.9% year-over-year to $459000.0; the TTM value through Sep 2025 reached $459000.0, down 69.9%, while the annual FY2024 figure was $679000.0, 65.9% down from the prior year.
  • Inventory reached $459000.0 in Q3 2025 per BTAI's latest filing, down from $506000.0 in the prior quarter.
  • Across five years, Inventory topped out at $2.7 million in Q2 2024 and bottomed at $459000.0 in Q3 2025.
  • Average Inventory over 4 years is $1.5 million, with a median of $1.5 million recorded in 2024.
  • Peak YoY movement for Inventory: skyrocketed 186.22% in 2023, then tumbled 81.12% in 2025.
  • A 4-year view of Inventory shows it stood at $2.0 million in 2022, then increased by 0.3% to $2.0 million in 2023, then tumbled by 65.9% to $679000.0 in 2024, then plummeted by 32.4% to $459000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $459000.0 in Q3 2025, $506000.0 in Q2 2025, and $642000.0 in Q1 2025.